share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax制药 | 8-K：重大事件
美股sec公告 ·  05/17 16:13
Moomoo AI 已提取核心信息
Virpax Pharmaceuticals, Inc. successfully completed a public offering on May 17, 2024, raising approximately $2.25 million in gross proceeds. The offering included 937,034 shares of common stock, pre-funded warrants for 729,633 shares, and two series of common stock purchase warrants for up to 1,666,667 shares each. The funds are intended for working capital, general corporate purposes, and potentially to settle a portion of a company obligation under a settlement agreement. The securities were offered following a registration statement on Form S-1 that became effective on May 14, 2024. In connection with the offering, Virpax entered into a securities purchase agreement and a placement agency agreement with A.G.P./Alliance Global Partners, who acted as the placement agent. The company has agreed not to issue any additional shares or equivalents for 60 days post-offering and is restricted from certain types of equity transactions for six months. Following the offering and the exercise of certain pre-funded warrants, Virpax has 2,741,600 shares of common stock outstanding.
Virpax Pharmaceuticals, Inc. successfully completed a public offering on May 17, 2024, raising approximately $2.25 million in gross proceeds. The offering included 937,034 shares of common stock, pre-funded warrants for 729,633 shares, and two series of common stock purchase warrants for up to 1,666,667 shares each. The funds are intended for working capital, general corporate purposes, and potentially to settle a portion of a company obligation under a settlement agreement. The securities were offered following a registration statement on Form S-1 that became effective on May 14, 2024. In connection with the offering, Virpax entered into a securities purchase agreement and a placement agency agreement with A.G.P./Alliance Global Partners, who acted as the placement agent. The company has agreed not to issue any additional shares or equivalents for 60 days post-offering and is restricted from certain types of equity transactions for six months. Following the offering and the exercise of certain pre-funded warrants, Virpax has 2,741,600 shares of common stock outstanding.
Virpax Pharmicals, Inc. 于 2024 年 5 月 17 日成功完成了公开募股，总收益约为 225 万美元。此次发行包括937,034股普通股、729,633股的预先注资认股权证，以及两系列普通股购买认股权证，每份不超过1,666,667股。这些资金用于营运资金、一般公司用途，并可能用于偿还和解协议下的部分公司债务。这些证券是在S-1表格的注册声明之后发行的，该声明于2024年5月14日生效。在这次发行中，Virpax与担任配售代理人的A.G.P./Alliance Global Partners签订了证券购买协议和配售代理协议。该公司已同意在发行后的60天内不发行任何额外股票或等价物，并且在六个月内被限制进行某些类型的股权交易。在发行和行使某些预先注资的认股权证之后，Virpax拥有2741,600股已发行普通股。
Virpax Pharmicals, Inc. 于 2024 年 5 月 17 日成功完成了公开募股，总收益约为 225 万美元。此次发行包括937,034股普通股、729,633股的预先注资认股权证，以及两系列普通股购买认股权证，每份不超过1,666,667股。这些资金用于营运资金、一般公司用途，并可能用于偿还和解协议下的部分公司债务。这些证券是在S-1表格的注册声明之后发行的，该声明于2024年5月14日生效。在这次发行中，Virpax与担任配售代理人的A.G.P./Alliance Global Partners签订了证券购买协议和配售代理协议。该公司已同意在发行后的60天内不发行任何额外股票或等价物，并且在六个月内被限制进行某些类型的股权交易。在发行和行使某些预先注资的认股权证之后，Virpax拥有2741,600股已发行普通股。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息